NASDAQ:BMEA Biomea Fusion (BMEA) Stock Forecast, Price & News $38.24 +0.70 (+1.86%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$37.54▼$39.1750-Day Range$23.98▼$38.2452-Week Range$5.30▼$39.17Volume1.14 million shsAverage Volume622,199 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$40.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biomea Fusion MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5.3% Upside$40.29 Price TargetShort InterestBearish19.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 5 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthDecreasingFrom ($3.54) to ($3.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 starsMedical Sector911th out of 981 stocksPharmaceutical Preparations Industry430th out of 460 stocks 2.5 Analyst's Opinion Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.29, Biomea Fusion has a forecasted upside of 5.3% from its current price of $38.24.Amount of Analyst CoverageBiomea Fusion has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.69% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Biomea Fusion has recently increased by 1.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BMEA. Previous Next 1.1 News and Social Media Coverage News SentimentBiomea Fusion has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $12,000,000.00 in company stock and sold $12,604,750.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders26.27% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.28% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Biomea Fusion are expected to decrease in the coming year, from ($3.54) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 10.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biomea Fusion (NASDAQ:BMEA) StockBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Stock News HeadlinesJune 6, 2023 | benzinga.comBiomea Fusion Unusual Options Activity For June 06June 5, 2023 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $2,535,750.00 in StockJune 7, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 2, 2023 | fool.comBiomea Fusion (NASDAQ: BMEA)May 28, 2023 | seekingalpha.comBiomea: Novel Approach To Diabetes And CancerMay 23, 2023 | nasdaq.comSGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were CulledMay 22, 2023 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Price Target Lowered to $53.00 at CitigroupMay 21, 2023 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives $40.57 Average Price Target from AnalystsJune 7, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 18, 2023 | msn.comCitigroup Maintains Biomea Fusion (BMEA) Buy RecommendationMay 12, 2023 | msn.comBiomea Fusion Surges on New Buy RatingMay 12, 2023 | msn.comBarclays Initiates Coverage of Biomea Fusion (BMEA) with Overweight RecommendationMay 12, 2023 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Coverage Initiated at BarclaysMay 12, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Aveanna Healthcare Holdings (AVAH)May 11, 2023 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $3,399,000.00 in StockMay 8, 2023 | msn.comUnusual Call Option Trade in Biomea Fusion (BMEA) Worth $686.20KMay 8, 2023 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Biomea Fusion (BMEA)May 6, 2023 | finanznachrichten.deBiomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate HighlightsMay 5, 2023 | americanbankingnews.comHC Wainwright Comments on Biomea Fusion, Inc.'s Q2 2023 Earnings (NASDAQ:BMEA)May 3, 2023 | msn.comHC Wainwright & Co. Reiterates Biomea Fusion (BMEA) Buy RecommendationMay 2, 2023 | msn.comRecap: Biomea Fusion Q1 EarningsMay 2, 2023 | finance.yahoo.comBiomea Fusion Reports First Quarter 2023 Financial Results and Corporate HighlightsMay 1, 2023 | marketwatch.comBiomea Fusion Receives FDA Clearance for Leukemia Inhibitor's Investigational New Drug AppMay 1, 2023 | finance.yahoo.comBiomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaApril 29, 2023 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $5,824,000.00 in StockApril 28, 2023 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives $39.00 Consensus PT from AnalystsApril 26, 2023 | seekingalpha.comBMEA Biomea Fusion, Inc.See More Headlines BMEA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMEA Company Calendar Last Earnings3/28/2023Today6/06/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.29 High Stock Price Forecast$53.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+6.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-79.98% Return on Assets-68.90% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.69 per share Price / Book10.30Miscellaneous Outstanding Shares35,400,000Free Float26,100,000Market Cap$1.35 billion OptionableNot Optionable Beta-1.04 Key ExecutivesMr. Thomas Andrew Butler (Age 41)Co-Founder, Chairman & CEO Comp: $772.86kMr. Ramses M. Erdtmann (Age 59)Co-Founder, Pres, COO & Director Comp: $570.57kMr. Franco Valle (Age 41)CFO & Principal Accounting Officer Comp: $251.69kMr. Heow Tan (Age 63)Chief Technology & Quality Officer Ms. Naomi CretcherChief People OfficerDr. Thorsten Kirschberg Ph.D. (Age 52)Exec. VP of Chemistry Dr. Stephan Morris M.D.Chief Medical OfficerMr. Ravi UpasaniSr. VP of Intellectual PropertyMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDCrinetics PharmaceuticalsNASDAQ:CRNXCTI BioPharmaNASDAQ:CTICTravere TherapeuticsNASDAQ:TVTXCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsA2a Pharmaceuticals, Inc.Sold 75,000 sharesTotal: $2.54 M ($33.81/share)JPMorgan Chase & Co.Sold 34,913 shares on 5/18/2023Ownership: 0.467%Baker BROS. Advisors LPBought 4,390 shares on 5/16/2023Ownership: 5.973%State Street CorpBought 4,600 shares on 5/16/2023Ownership: 0.159%Sandia Investment Management LPBought 10,000 shares on 5/16/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions BMEA Stock - Frequently Asked Questions Should I buy or sell Biomea Fusion stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks. What is Biomea Fusion's stock price forecast for 2023? 7 equities research analysts have issued twelve-month price objectives for Biomea Fusion's stock. Their BMEA share price forecasts range from $22.00 to $53.00. On average, they predict the company's stock price to reach $40.29 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts. How have BMEA shares performed in 2023? Biomea Fusion's stock was trading at $8.43 at the beginning of 2023. Since then, BMEA shares have increased by 350.8% and is now trading at $38.00. View the best growth stocks for 2023 here. When is Biomea Fusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our BMEA earnings forecast. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) issued its earnings results on Tuesday, March, 28th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05. What ETFs hold Biomea Fusion's stock? ETFs with the largest weight of Biomea Fusion (NASDAQ:BMEA) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), When did Biomea Fusion IPO? (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO. What is Biomea Fusion's stock symbol? Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA." Who are Biomea Fusion's major shareholders? Biomea Fusion's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (7.57%), Baker BROS. Advisors LP (5.97%), BlackRock Inc. (2.78%), Perceptive Advisors LLC (0.92%), Geode Capital Management LLC (0.60%) and JPMorgan Chase & Co. (0.47%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biomea Fusion's stock price today? One share of BMEA stock can currently be purchased for approximately $38.00. How much money does Biomea Fusion make? Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $1.35 billion. The company earns $-81,830,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis. How can I contact Biomea Fusion? The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com. This page (NASDAQ:BMEA) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.